Broad Clinical Labs to Bring On Nomic Bio’s Proteomic Assays

The companies will integrate Nomic's Omni 1000 platform into BCL's offerings, with jointly developed solutions targeted for broad availability in early 2027.

Montreal-based Nomic Bio and Broad Clinical Labs (BCL) have announced a partnership to integrate Nomic’s Omni 1000 proteomics platform into BCL’s multiomic workflows.

“One of the longstanding challenges has been making proteomic data as scalable, usable, and comparable as other core modalities,” Niall Lennon, Chief Scientific Officer of Broad Clinical Laboratories, said in a statement. “Nomic brings an approach that helps address that need.

Initial development is already underway; the companies plan to offer jointly developed solutions by early 2027. Financial terms of the partnership were not disclosed.

At the center of the collaboration, announced April 20, is the Nomic Omni 1000, which is based on the company’s nELISA technology and measures over 1,050 biologically relevant proteins. The platform is designed to quantify proteins in translational studies, clinical programs, and multiomic research efforts.

Planned applications include combining polygenic risk models with proteomic signals for disease prevention and early detection; pairing proteomic profiling with liquid biopsy and for biomarker discovery and treatment-response monitoring in cancer; and population-scale multiomic studies of diseases.